Cited by 2,207Cancer Genomics and DiagnosticsBRCA gene mutations in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Open access

Dawson, Sarah-Jane, Tsui, Dana W.Y., Murtaza, Muhammed, Biggs, Heather, Rueda, Oscar M., Chin, Suet-Feung, Dunning, Mark J., Gale, Davina, Forshew, Tim, Mahler-Araujo, Betania, Rajan, Sabrina, Humphray, Sean, Becq, Jennifer, Halsall, David, Wallis, Matthew, Bentley, David, Caldas, Carlos, Rosenfeld, Nitzan·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1213261

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer. METHODS: We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and numbers of circulating tumor cells were measured at identical time points. RESULTS: Circulating tumor DNA was successfully detected in 29 of the 30 women (97%) in whom somatic genomic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women (78%) and 26 of 30 women (87%), respectively. Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells. Among the measures tested, circulating tumor DNA provided the earliest measure of treatment response in 10 of 19 women (53%). CONCLUSIONS: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer. (Funded by Cancer Research UK and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1213261

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citation
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V. D., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S. R., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,595
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Lauro S, 1999, Anticancer Res, 19, 3511
Chen X, 1999, Clin Cancer Res, 5, 2297

Sorted by citations

Items 701–800 of 1,003

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Josephs, D. H., & Sarker, D. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30529 · Cited by 49
Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis
Lin, Z., Neiswender, J. V., Fang, B., Ma, X., Zhang, J., & Hu, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15775 · Cited by 46
An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer
Mayo‐de‐las‐Casas, C., Garzón‐Ibáñez, M., Jordana‐Ariza, N., García‐Peláez, B., Balada‐Bel, A., Villatoro, S., Malapelle, U., Karachaliou, N., Troncone, G., Rosell, R., et al. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1407243 · Cited by 47
Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges
Rodda, A. E., Parker, B. J., Spencer, A. G., & Corrie, S. R. (2018) · ACS Sensors · doi:10.1021/acssensors.7b00953 · Cited by 46
Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors
Aghamir, S. M. K., Heshmat, R., Ebrahimi, M., & Khatami, F. (2020) · Epigenetics Insights · doi:10.1177/2516865720904052 · Cited by 47
Emerging Immunotherapies in the Treatment of Brain Metastases
Nieblas‐Bedolla, E., Nayyar, N., Singh, M., Sullivan, R. J., & Brastianos, P. K. (2020) · The Oncologist · doi:10.1002/onco.13575 · Cited by 48
High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system
Tan, Y., Tang, T., Xu, H., Zhu, C., & Cunningham, B. T. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.05.041 · Cited by 46
Liquid biopsies for residual disease and recurrence
Wan, J. C. M., Mughal, T. I., Razavi, P., Dawson, S., Moss, E. L., Govindan, R., Tan, I. B., Yap, Y. S., Robinson, W. A., Morris, C. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.001 · Cited by 48
Self-citation
Design of a Lab-On-Chip for Cancer Cell Detection through Impedance and Photoelectrochemical Response Analysis
Hsiao, Y., Mukundan, A., Chen, W., Wu, M., Hsieh, S.-C., & Wang, H. (2022) · Biosensors · doi:10.3390/bios12060405 · Cited by 45
Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers
Addanki, S., Meas, S., Sarli, V. N., Singh, B., & Lucci, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147843 · Cited by 45
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Stone, A. M., Cowley, M. J., Valdés‐Mora, F., McCloy, R. A., Sergio, C. M., Gallego‐Ortega, D., Caldon, C. E., Ormandy, C. J., Biankin, A. V., Gee, J. M. W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0012 · Cited by 45
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
Tachtsidis, A., McInnes, L. M., Jacobsen, N., Thompson, E. W., & Saunders, C. M. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-016-9796-8 · Cited by 47
Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
Cabel, L., Proudhon, C., Mariani, P., Tzanis, D., Beinse, G., Bièche, I., Pierga, J., & Bidard, F. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.01.010 · Cited by 46
Circulating Tumor DNA for Early Cancer Detection
Fiala, C., Kulasingam, V., & Diamandis, E. P. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.026393 · Cited by 45
RETRACTED ARTICLE: Long non-coding RNA LINC00968 reduces cell proliferation and migration and angiogenesis in breast cancer through up-regulation of PROX1 by reducing hsa-miR-423-5p
Sun, X., Huang, T., Zhang, C., Zhang, S., Wang, Y., Zhang, Q., & Liu, Z. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1632641 · Cited by 45
Retracted
A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer
Shinjo, K., Hara, K., Nagae, G., Umeda, T., Katsushima, K., Suzuki, M. M., Murofushi, Y., Umezu, Y., Takeuchi, I., Takahashi, S., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233782 · Cited by 45
Serum microRNA is a biomarker for post-operative monitoring in glioma
Morokoff, A. P., Jones, J., Nguyen, H. P. T., Ma, C., Lasocki, A., Gaillard, F., Bennett, I. E., Luwor, R. B., Stylli, S. S., Paradiso, L., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03566-w · Cited by 45
Preclinical models and technologies to advance nanovaccine development
Peres, C., Matos, A. I., Moura, L. I. F., Acúrcio, R. C., Carreira, B., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Satchi‐Fainaro, R., & Florindo, H. F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.001 · Cited by 45
Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools
Garcia, J., Kamps‐Hughes, N., Geiguer, F., Couraud, S., Sarver, B. A. J., Payen, L. F., & Ionescu‐Zanetti, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-89592-8 · Cited by 46
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
Abbou, S., Klega, K., Tsuji, J., Tanhaemami, M., Hall, D., Barkauskas, D. A., Krailo, M. D., Cibulskis, C., Nag, A., Thorner, A. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00409 · Cited by 44
Increasing the Sensitivity of Electrochemical DNA Detection by a Micropillar-Structured Biosensing Surface
Movilli, J., Kolkman, R. W., Rozzi, A., Corradini, R., Segerink, L. I., & Huskens, J. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c00144 · Cited by 43
Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids
Lewis, J. M., Heineck, D. P., & Heller, M. J. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1069709 · Cited by 44
Evolving paradigms in multifocal breast cancer
Salgado, R., Aftimos, P. G., Sotiriou, C. P., & Desmedt, C. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.002 · Cited by 44
Molecular Concordance Between Primary Breast Cancer and Matched Metastases
Krøigård, A. B., Larsen, M. J., Thomassen, M., & Kruse, T. A. (2016) · The Breast Journal · doi:10.1111/tbj.12596 · Cited by 44
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Tomiguchi, M., Sueta, A., Murakami, K., Omoto, Y., & Iwase, H. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.07.004 · Cited by 44
The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Barry, P. A., Vatsiou, A. I., Spiteri, I., Nichol, D., Cresswell, G. D., Acar, A., Trahearn, N., Hrebien, S., García-Murillas, I., Chkhaidze, K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3374 · Cited by 43
Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ
Kumar, S., Lindsay, D., Chen, Q. B., Garrett, A., Tan, X. M., Anders, C. K., Carey, L., & Gupta, G. P. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0093-3 · Cited by 44
A Snapshot of The Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy
Herrera, M., Galindo-Pumariño, C., García‐Barberán, V., & Peña, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236016 · Cited by 45
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
Thibault, B., Ramos‐Delgado, F., Tostivint, E. P., Therville, N., Cintas, C., Arcucci, S., Cassant‐Sourdy, S., Reyes‐Castellanos, G., Tosolini, M., Villard, A. V., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013502 · Cited by 46
From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube
Maaß, K. K., Schad, P. S., Finster, A. M. E., Puranachot, P., Rosing, F., Wedig, T., Schwarz, N., Stumpf, N., Pfister, S. M., & Pajtler, K. W. (2021) · Cancers · doi:10.3390/cancers13123002 · Cited by 44
The Role of Circulating Biomarkers in Lung Cancer
Herath, S., Sadeghirad, H., Radfar, P., Ladwa, R., Warkiani, M. E., O'Byrne, K. J., & Kulasinghe, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.801269 · Cited by 47
Plasma Circulating Cell-free Nuclear and Mitochondrial DNA as Potential Biomarkers in the Peripheral Blood of Breast Cancer Patients
Mahmoud, E. H., Fawzy, A., Ahmad, O. K., & Ali, A. M. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.18.8299 · Cited by 44
Frequent Tumor Burden Monitoring of Esophageal Squamous Cell Carcinoma With Circulating Tumor DNA Using Individually Designed Digital Polymerase Chain Reaction
Iwaya, T., Endo, F., Yaegashi, M., Sasaki, N., Fujisawa, R., Hiraki, H., Akiyama, Y., Sasaki, A., Suzuki, Y., Masuda, M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.09.035 · Cited by 43
Genomic Sequencing for Cancer Diagnosis and Therapy
Wang, L., & Wheeler, D. A. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-120811-171056 · Cited by 44
A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma
Xie, G., Gu, D., Zhang, L., Chen, S., & Wu, D. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1345389 · Cited by 44
Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA
Carow, K., Gölitz, M., Wolf, M., Häfner, N., Jansen, L., Hoyer, H., Schwarz, E., Runnebaum, I. B., & Dürst, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102032 · Cited by 43
Precision Medicine in Hormone Receptor-Positive Breast Cancer
Nasrazadani, A., Thomas, R. A., Oesterreich, S., & Lee, A. V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00144 · Cited by 46
Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer
Lee, J. H., Jeong, H., Choi, J.-W., Oh, H. E., & Kim, Y. (2018) · Medicine · doi:10.1097/md.0000000000012862 · Cited by 43
The current status of the clinical utility of liquid biopsies in cancer
Snow, A. E., Chen, D., & Lang, J. E. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1664290 · Cited by 44
Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-κB induced cell death
Bhatelia, K., Singh, A., Tomar, D., Singh, K., Sripada, L., Chagtoo, M., Prajapati, P., Singh, R. K., Godbole, M. M., & Singh, R. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.11.006 · Cited by 43
A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0987 · Cited by 42
The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Wang, H., Zhou, F., Qiao, M., Li, X., Zhao, C., Cheng, L., Chen, X., & Zhou, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671874 · Cited by 42
The Promise of Circulating Tumor DNA in Head and Neck Cancer
Aulakh, S. S., Silverman, D. A., Young, K., Dennis, S. K., & Birkeland, A. C. (2022) · Cancers · doi:10.3390/cancers14122968 · Cited by 44
Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease
Inns, J., & James, V. H. (2015) · The Breast · doi:10.1016/j.breast.2015.04.001 · Cited by 43
Circulating tumor cells in breast cancer—current status and perspectives
Banys-Paluchowski, M. J., Krawczyk, N., Meier-Stiegen, F., & Fehm, T. N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.010 · Cited by 42
Capture and Release of Cancer Cells Based on Sacrificeable Transparent MnO2 Nanospheres Thin Film
Huang, Q., Chen, B., He, R., He, Z., Cai, B., Xu, J., Qian, W., Chan, H. L. W., Liu, W., Guo, S., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300670 · Cited by 42
Circulating Biomarkers for Prediction of Treatment Response
Cappelletti, V., Appierto, V., Tiberio, P., Fina, E., Callari, M., & Daidone, M. G. (2015) · JNCI Monographs · doi:10.1093/jncimonographs/lgv006 · Cited by 43
New blood markers detection technology: A leap in the diagnosis of gastric cancer
Beeharry, M. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1202 · Cited by 42
Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer
Hyun, M. H., Sung, J. S., Kang, E. J., Choi, Y. J., Park, K. H., Shin, S. W., Lee, S. Y., & Kim, Y. H. (2017) · Oncotarget · doi:10.18632/oncotarget.21769 · Cited by 42
Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer
Reinert, T., Gonçalves, R., & Bines, J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0542-0 · Cited by 44
Tumour biomarkers—Tracing the molecular function and clinical implication
Lin, J., Ma, L., Zhang, D., Gao, J., Jin, Y., Han, Z., & Lin, D. (2019) · Cell Proliferation · doi:10.1111/cpr.12589 · Cited by 42
Overview of Molecular Testing of Cytology Specimens
Huang, M., & Wei, S. (2019) · Acta Cytologica · doi:10.1159/000497187 · Cited by 42
Assessment of circulating copy number variant detection for cancer screening
Molparia, B., Nichani, E., & Torkamani, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180647 · Cited by 43
Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes
Yang, W.-Y., Feng, L., Meng, X. L., Chen, R., Xu, W.-H., Hou, J., Xu, T., & Zhang, L. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1855977 · Cited by 42
Breast Cancer Heterogeneity in Primary and Metastatic Disease
Kalinowski, L., Saunus, J. M., Reed, A. E. M., & Lakhani, S. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_6 · Cited by 47
Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy
Lin, P., Wang, M., Lo, C., Tsai, L., Yen, T., Huang, T. Y., Huang, W., Yang, K., Chen, C., Fan, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.736769 · Cited by 42
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533
Madanat-Harjuoja, L. M., Renfro, L. A., Klega, K., Tornwall, B., Thorner, A. R., Nag, A., Dix, D., Dome, J. S., Diller, L. R., Fernandez, C. V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00098 · Cited by 41
Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
Iwama, E., Sakai, K., Azuma, K., Harada, D., Nosaki, K., Hotta, K., Nishio, M., Kurata, T., Fukuhara, T., Akamatsu, H., et al. (2018) · Cancer Science · doi:10.1111/cas.13820 · Cited by 41
Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion
Akamatsu, H., Koh, Y., Kenmotsu, H., Naito, T., Serizawa, M., Kimura, M., Mori, K. P., Imai, H., Ono, A., Shukuya, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000203 · Cited by 41
Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR
Ashida, A., Sakaizawa, K., Mikoshiba, A., Uhara, H., & Okuyama, R. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-0976-y · Cited by 41
Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer
Zhou, J., Chang, L., Guan, Y., Yang, L., Xia, X., Cui, L., Yi, X., & Lin, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159708 · Cited by 41
Single Domain Antibodies as New Biomarker Detectors
Leow, C. H., Fischer, K., Leow, C. Y., Cheng, Q., Chuah, C., & McCarthy, J. S. (2017) · Diagnostics · doi:10.3390/diagnostics7040052 · Cited by 44
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
Rowe, S. P., Luber, B. S., Makell, M., Brothers, P., Santmyer, J., Schollenberger, M. D., Quinn, H., Edelstein, D. L., Jones, F. S., Bleich, K. B., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12373 · Cited by 42
Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance
Wang, S., Yeh, S., & Chen, P. (2021) · Cancers · doi:10.3390/cancers13102454 · Cited by 42
Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy
Cimadamore, A., Gasparrini, S., Massari, F., Santoni, M., Liang Cheng, C., Antonio Lopez-beltran, B., Scarpelli, M., & Montironi, R. (2019) · Cancers · doi:10.3390/cancers11020196 · Cited by 40
Liquid biopsy: Cell-free DNA based analysis in breast cancer
Venetis, K., Cursano, G., Pescia, C., D’Ercole, M., Porta, F. M., Blanco, M. C., Frascarelli, C., Ivanova, M. D., Guerini‐Rocco, E., & Fusco, N. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100002 · Cited by 44
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 43
Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments
Stover, D. G., & Wagle, N. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0438-0 · Cited by 39
The significance of circulating tumour cells in breast cancer: A review
Castle, J., Shaker, H., Morris, K. L., Tugwood, J. D., & Kirwan, C. (2014) · The Breast · doi:10.1016/j.breast.2014.07.002 · Cited by 44
Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma
Majer, W., Kluzek, K., Bluyssen, H. A. R., & Wesoły, J. (2015) · Journal of Cancer · doi:10.7150/jca.12145 · Cited by 40
Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence
Cheng, J., Ćuk, K., Heil, J., Golatta, M., Schott, S., Sohn, C., Schneeweiß, A., Burwinkel, B., & Surowy, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17384 · Cited by 42
Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST
Xu, H., Chen, L., Shao, Y. W., Zhu, D., Zhi, X., Zhang, Q., Li, F., Xu, J., Liu, X.-S., & Xu, Z. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0436 · Cited by 40
Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer Therapy
Oellerich, M., Schütz, E., Beck, J., & Walson, P. D. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000566 · Cited by 39
Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies
Jiang, P., Chan, K. C. A., & Lo, Y. M. D. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.003 · Cited by 41
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis
Li, B., Pu, K., Ge, L., & Wu, X. (2019) · Gene · doi:10.1016/j.gene.2019.143993 · Cited by 41
Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer
Lyskjær, I., Kronborg, C. J. S., Rasmussen, M. H., Sørensen, B. S., Demuth, C., Rosenkilde, M., Frydendahl, A., Knudsen, M., Vang, S., Krag, S. R. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47708-1 · Cited by 43
Phylogenomics, biogeography, and evolution of morphology and ecological niche of the eastern Asian–eastern North AmericanNyssa(Nyssaceae)
Zhou, W., Xiang, Q., & Wen, J. (2020) · Journal of Systematics and Evolution · doi:10.1111/jse.12599 · Cited by 39
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors
Li, J., Jiang, W., Wei, J., Zhang, J., Cai, L., Luo, M., Wang, Z., Sun, W., Wang, S., Wang, C., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02449-y · Cited by 42
Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
Woo, H. J., Kim, S., Kang, H. J., Lee, S., Lee, S. J., Kim, J. M., Gurel, O., Kim, S. Y., Roh, H. R., Lee, J., et al. (2022) · Theranostics · doi:10.7150/thno.72511 · Cited by 41
Targeting cancer epigenetics: Linking basic biology to clinical medicine
Shinjo, K., & Kondo, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.006 · Cited by 39
Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons
Andersen, R. F., Spindler, K. G., Brandslund, I., Jakobsen, A. K. M., & Pallisgaard, N. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.011 · Cited by 40
Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Irizarry-Alvarado, J. M., Dwyer, J. P., Brumble, L. M., Álvarez, S., & Mendez, J. (2009) · PubMed · Cited by 39
Combinatorial Power of cfDNA, CTCs and EVs in Oncology
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040870 · Cited by 40
Tracking tumor resistance using 'liquid biopsies'
Pantel, K., Diaz, L. A., & Polyák, K. (2013) · Nature Medicine · doi:10.1038/nm.3233 · Cited by 38
Digital PCR analysis of circulating tumor DNA: A biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection
Gutteridge, A., Rathbone, V. M., Gibbons, R., Bi, M., Archard, N., Davies, K. E. J., Brown, J., Plagnol, V., Pillay, N., Amary, F., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1146 · Cited by 38
Self-citation
Using all our genomes: Blood‐based liquid biopsies for the early detection of cancer
Adams, E. W., Sepich‐Poore, G. D., Miller‐Montgomery, S., & Knight, R. D. (2022) · Open Research (University of Surrey) · doi:10.1002/viw.20200118 · Cited by 38
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
Soultati, A. S., Stares, M., Swanton, C., Larkin, J., & Turajlic, S. (2015) · Current Opinion in Urology · doi:10.1097/mou.0000000000000204 · Cited by 37
Changing paradigm of cancer therapy: precision medicine by next-generation sequencing
Xue, Y. C., Xue, Y. C., Wilcox, W. R., & Wilcox, W. R. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0003 · Cited by 39
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma
Mellert, H. S., Foreman, T. M., Jackson, L. P., Maar, D., Thurston, S., Koch, K., Weaver, A., Cooper, S., Dupuis, N., Sathyanarayana, U. G., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.004 · Cited by 37
The Mutational Landscape of Gastrointestinal Malignancies as Reflected by Circulating Tumor DNA
Riviere, P. J., Fanta, P. T., Ikeda, S., Baumgartner, J. M., Heestand, G. M., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0360 · Cited by 39
Centrifugation-free extraction of circulating nucleic acids using immiscible liquid under vacuum pressure
Lee, H., Na, W., Park, C., Park, K. H., & Shin, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23766-9 · Cited by 38
Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer
Shang, M., Chang, C., Pei, Y., Guan, Y., Chang, J., & Li, H. (2018) · Journal of Cancer · doi:10.7150/jca.28458 · Cited by 37
Stable Colloidosomes Formed by Self-Assembly of Colloidal Surfactant for Highly Robust Digital PCR
Yin, K., Zeng, X., Liu, W., Xue, Y., Li, X., Wang, W., Song, Y., Zhu, Z., & Yang, C. J. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00470 · Cited by 38
Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
Červená, K., Vodička, P., & Vymetalkova, V. P. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2019.05.002 · Cited by 42
Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
Filipska, M., & Rosell, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12983 · Cited by 38
Raman spectroscopy reveals phenotype switches in breast cancer metastasis
Paidi, S. K., Troncoso, J. R., Harper, M. G., Liu, Z., Nguyen, K. G., Ravindranathan, S., Rebello, L., Lee, D. E., Ivers, J. D., Zaharoff, D. A., et al. (2022) · Theranostics · doi:10.7150/thno.74002 · Cited by 39
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients
Deligezer, U., Bronkhorst, A. J., & Holdenrieder, S. (2022) · Diagnostics · doi:10.3390/diagnostics12123042 · Cited by 38
Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer
Jaworski, J. J., Morgan, R. D., & Sivakumar, S. (2020) · Cancers · doi:10.3390/cancers12123704 · Cited by 39
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Yang, J., Yan, H., Zhang, Y.-X., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725938 · Cited by 37
Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma
Fu, S. W., Tang, C., Tan, X., & Srivastava, S. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2408744 · Cited by 41

Authors: Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., & Rosenfeld, N.
Affiliations: University of Cambridge (GB)
National Health Service (GB)
ORCID: Dawson, Sarah-Jane
Tsui, Dana W.Y.
Murtaza, Muhammed
Biggs, Heather
Rueda, Oscar M.
Chin, Suet-Feung
Dunning, Mark J.
Gale, Davina
Forshew, Tim
Mahler-Araujo, Betania
Humphray, Sean
Halsall, David
Wallis, Matthew
Caldas, Carlos
Rosenfeld, Nitzan
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-03-28
Volume: 368
Issue: 13
Pages: 1199-1209
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1213261
OpenAlex: W2140575188
Cited by: 2,207
References: 44
Citations by year: 2026: 86 · 2025: 96 · 2024: 106 · 2023: 109 · 2022: 169 · 2021: 180 · 2020: 197 · 2019: 220 · 2018: 197 · 2017: 224 · 2016: 204 · 2015: 195 · 2014: 135 · 2013: 82
FWCI: 72.15
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Cancer Research UK (11906, 16942, 22310)
National Institute for Health and Care Research (NF-SI-0611-10154)
NIHR Cambridge Biomedical Research Centre
Cancer Research UK Cambridge Institute, University of Cambridge
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: circulating tumor DNA, metastatic breast cancer, liquid biopsy, CA15-3, circulating tumor cells, treatment response monitoring, tumor burden, somatic alterations, circulating biomarkers, early detection of treatment response
MeSH terms: Breast Neoplasms, DNA, Neoplasm, Female, Humans, Mutation, Neoplasm Metastasis, Prognosis, Radiography, Sensitivity and Specificity, Biomarkers, Tumor, Sequence Analysis, DNA, Mucin-1, Tumor Burden, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks